Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARYA Sciences Acquisition Corp VARYE · Entity 137308 | Director | July 12, 2021 | July 13, 2021 |
| ASCENTAGE PHARMA GROUP INTERNATIONALAAPG · Entity 4672 | Director | March 18, 2026 | March 23, 2026 |
| LianBioLIAN · Entity 9881 | See Remarks | May 04, 2022 | May 06, 2022 |
| MeiraGTx Holdings plcMGTX · Entity 4734 | Director | June 11, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARYA Sciences Acquisition Corp V
Report date July 12, 2021 · Filed July 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
ASCENTAGE PHARMA GROUP INTERNATIONAL
Report date March 18, 2026 · Filed March 23, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2035-11-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance Not disclosed F2: The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. F1: The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025. F4: The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission. |
| Restricted share unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed F3: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. F4: The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.
F2: The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.
F3: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
F4: The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.
LianBio
Report date May 04, 2022 · Filed May 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,000,000 |
Reported balance
After 2022-05-04 transaction · row 1
1 source rowRow 1 · 2022-05-04 · Exercise / conversion · Acquired 1,000,000 · Balance 1,000,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2030-01-01 | Direct | 999,947 |
Reported balance
After 2022-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-04 · Exercise / conversion · Disposed 1,000,000 · Balance 999,947 F1: 1/3 of the shares underlying the option vested and became exercisable on January 1, 2020; 1/3 of the shares underlying the option vested and became exercisable on October 1, 2020 and 1/3 of the shares underlying the option vested and became exercisable on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/3 of the shares underlying the option vested and became exercisable on January 1, 2020; 1/3 of the shares underlying the option vested and became exercisable on October 1, 2020 and 1/3 of the shares underlying the option vested and became exercisable on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date.
MeiraGTx Holdings plc
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 60,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 60,000 · Balance 60,000 F1: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F2: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 11, 2027 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director.
F2: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 11, 2027 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 16, 2026 00:56 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantRestricted Share Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001869480-26-000002 · form4-06162026_120619.xml · derivative · entry 1 Yu Debra · CIK 0001869480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F2 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 11, 2027 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2027. F2 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 11, 2027 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2027. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 01:15 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantRestricted Share Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017459 · form4-06172025_010602.xml · derivative · entry 1 Yu Debra · CIK 0001869480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F2 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 12, 2026 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2026. F2 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 12, 2026 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2026. Read SEC document |
| June 06, 2024 Filed Jun 6, 2024 20:44 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantRestricted Share Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015783 · form4-06062024_080610.xml · derivative · entry 1 Yu Debra · CIK 0001869480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F2 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 6, 2025 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2025. F2 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 6, 2025 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2025. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:27 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantRestricted Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009616 · form4-06122023_080644.xml · derivative · entry 2 Yu Debra · CIK 0001869480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The reporting person elected to have the restricted share units become settleable when the reporting person ceases to be a director. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:27 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001415889-23-009616 · form4-06122023_080644.xml · derivative · entry 1 Yu Debra · CIK 0001869480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 8, 2024 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2024. Read SEC document |
| May 04, 2022 Filed May 6, 2022 20:15 UTC | LianBio LIAN · Entity 9881 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0000899243-22-017091 · doc4.xml · derivative · entry 2 Yu Debra · CIK 0001869480 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 999,947 Underlying: Ordinary Shares · 1,000,000 shares Expires 2030-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/3 of the shares underlying the option vested and became exercisable on January 1, 2020; 1/3 of the shares underlying the option vested and became exercisable on October 1, 2020 and 1/3 of the shares underlying the option vested and became exercisable on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| May 04, 2022 Filed May 6, 2022 20:15 UTC | LianBio LIAN · Entity 9881 | Exercise / conversionOrdinary Shares | 1,000,000 | $1.71 | $1,710,000.00 |
DisclosureSEC source: 0000899243-22-017091 · doc4.xml · nonDerivative · entry 1 Yu Debra · CIK 0001869480 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 21:03 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $12.85 | $0.00 |
DisclosureSEC source: 0001415889-22-004286 · form4-04272022_020422.xml · derivative · entry 1 Yu Debra · CIK 0001869480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2032-04-25 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments following the date of grant. Read SEC document |
| October 31, 2021 Filed Nov 1, 2021 23:19 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 747,227 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042211 · doc4.xml · derivative · entry 1 Yu Debra · CIK 0001869480 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,747,174 Underlying: Ordinary Shares · 747,227 shares Expires 2031-10-31 F1 · derivative.exercise_date: 1/4 of the shares underlying the option will vest and become exercisable on October 31, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.